Listed

Passage BIO, Inc.

PASGNasdaqCIK 1787297HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$8.3m, Q2 FY2026
Net income−$7.8m, Q2 FY2026
Passage BIO, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$mnot reportednot reported11.5Research and development, Q1 FY2024, three months to 2024-03-31$11.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-13, accession 0001558370-25-007489.Report this figure10.4Research and development, Q2 FY2024, three months to 2024-06-30$10.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-12, accession 0001558370-25-011146.Report this figure8.7Research and development, Q3 FY2024, three months to 2024-09-30$8.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-10, accession 0001104659-25-109180.Report this figure9.6Research and development, Q4 FY2024, three months to 2024-12-31$9.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-03, accession 0001104659-26-022549. Derived: 12-month figure less the 9-month figure.Report this figure7.7Research and development, Q1 FY2025, three months to 2025-03-31$7.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-12, accession 0001104659-26-058987.Report this figure5.8Research and development, Q2 FY2025, three months to 2025-06-30$5.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure4.3Research and development, Q3 FY2025, three months to 2025-09-30$4.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-10, accession 0001104659-25-109180.Report this figure5.4Research and development, Q4 FY2025, three months to 2025-12-31$5.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-03, accession 0001104659-26-022549. Derived: 12-month figure less the 9-month figure.Report this figure4.1Research and development, Q1 FY2026, three months to 2026-03-31$4.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-12, accession 0001104659-26-058987.Report this figure3.3Research and development, Q2 FY2026, three months to 2026-06-30$3.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure
Operating income$m(28.7)Operating income, Q3 FY2023, three months to 2023-09-30−$28.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-13, accession 0001558370-24-015431.Report this figure(18.4)Operating income, Q4 FY2023, three months to 2023-12-31−$18.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-04, accession 0001558370-25-002101. Derived: 12-month figure less the 9-month figure.Report this figure(18.1)Operating income, Q1 FY2024, three months to 2024-03-31−$18.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-13, accession 0001558370-25-007489.Report this figure(17.4)Operating income, Q2 FY2024, three months to 2024-06-30−$17.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-12, accession 0001558370-25-011146.Report this figure(20.7)Operating income, Q3 FY2024, three months to 2024-09-30−$20.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001104659-25-109180.Report this figure(14.3)Operating income, Q4 FY2024, three months to 2024-12-31−$14.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-03, accession 0001104659-26-022549. Derived: 12-month figure less the 9-month figure.Report this figure(16.5)Operating income, Q1 FY2025, three months to 2025-03-31−$16.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001104659-26-058987.Report this figure(10.3)Operating income, Q2 FY2025, three months to 2025-06-30−$10.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure(8.7)Operating income, Q3 FY2025, three months to 2025-09-30−$8.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001104659-25-109180.Report this figure(13.8)Operating income, Q4 FY2025, three months to 2025-12-31−$13.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-03, accession 0001104659-26-022549. Derived: 12-month figure less the 9-month figure.Report this figure(8.2)Operating income, Q1 FY2026, three months to 2026-03-31−$8.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001104659-26-058987.Report this figure(8.3)Operating income, Q2 FY2026, three months to 2026-06-30−$8.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure
Net income$m(27.1)Net income, Q3 FY2023, three months to 2023-09-30−$27.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-13, accession 0001558370-24-015431.Report this figure(16.8)Net income, Q4 FY2023, three months to 2023-12-31−$16.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-04, accession 0001558370-25-002101. Derived: 12-month figure less the 9-month figure.Report this figure(16.7)Net income, Q1 FY2024, three months to 2024-03-31−$16.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-13, accession 0001558370-25-007489.Report this figure(16.0)Net income, Q2 FY2024, three months to 2024-06-30−$16.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-12, accession 0001558370-25-011146.Report this figure(19.3)Net income, Q3 FY2024, three months to 2024-09-30−$19.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001104659-25-109180.Report this figure(12.7)Net income, Q4 FY2024, three months to 2024-12-31−$12.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-03, accession 0001104659-26-022549. Derived: 12-month figure less the 9-month figure.Report this figure(15.4)Net income, Q1 FY2025, three months to 2025-03-31−$15.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-12, accession 0001104659-26-058987.Report this figure(9.4)Net income, Q2 FY2025, three months to 2025-06-30−$9.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure(7.7)Net income, Q3 FY2025, three months to 2025-09-30−$7.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001104659-25-109180.Report this figure(13.0)Net income, Q4 FY2025, three months to 2025-12-31−$13.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-03, accession 0001104659-26-022549. Derived: 12-month figure less the 9-month figure.Report this figure(7.6)Net income, Q1 FY2026, three months to 2026-03-31−$7.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-12, accession 0001104659-26-058987.Report this figure(7.8)Net income, Q2 FY2026, three months to 2026-06-30−$7.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure
Diluted EPS$ per share(0.49)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.49 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-13, accession 0001558370-24-015431.Report this figurenot reported(0.30)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-13, accession 0001558370-25-007489.Report this figure(5.09)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$5.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-12, accession 0001558370-25-011146.Report this figure(6.15)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$6.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001104659-25-109180.Report this figurenot reported(4.87)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$4.87 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001104659-26-058987.Report this figure(2.96)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$2.96 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure(2.44)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$2.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001104659-25-109180.Report this figurenot reported(2.36)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$2.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001104659-26-058987.Report this figure(2.44)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$2.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure
Basic EPS$ per share(0.49)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.49 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-13, accession 0001558370-24-015431.Report this figurenot reported(0.30)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.30 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-13, accession 0001558370-25-007489.Report this figure(5.09)Basic EPS, Q2 FY2024, three months to 2024-06-30−$5.09 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-12, accession 0001558370-25-011146.Report this figure(6.15)Basic EPS, Q3 FY2024, three months to 2024-09-30−$6.15 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-10, accession 0001104659-25-109180.Report this figurenot reported(4.87)Basic EPS, Q1 FY2025, three months to 2025-03-31−$4.87 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-12, accession 0001104659-26-058987.Report this figure(2.96)Basic EPS, Q2 FY2025, three months to 2025-06-30−$2.96 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure(2.44)Basic EPS, Q3 FY2025, three months to 2025-09-30−$2.44 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-10, accession 0001104659-25-109180.Report this figurenot reported(2.36)Basic EPS, Q1 FY2026, three months to 2026-03-31−$2.36 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-12, accession 0001104659-26-058987.Report this figure(2.44)Basic EPS, Q2 FY2026, three months to 2026-06-30−$2.44 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure

Balance sheet

Cash and equivalents$24.2m, Q2 FY2026
Shareholders' equity$4.5m, Q2 FY2026
Passage BIO, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m33.6Cash and equivalents, Q3 FY2023, at 2023-09-30$33.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-13, accession 0001558370-23-018686.Report this figure21.7Cash and equivalents, FY2023, at 2023-12-31$21.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-04, accession 0001558370-25-002101.Report this figure36.8Cash and equivalents, Q1 FY2024, at 2024-03-31$36.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-14, accession 0001558370-24-008058.Report this figure24.8Cash and equivalents, Q2 FY2024, at 2024-06-30$24.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-08, accession 0001558370-24-011463.Report this figure32.3Cash and equivalents, Q3 FY2024, at 2024-09-30$32.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-13, accession 0001558370-24-015431.Report this figure37.6Cash and equivalents, FY2024, at 2024-12-31$37.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-03, accession 0001104659-26-022549.Report this figure63.4Cash and equivalents, Q1 FY2025, at 2025-03-31$63.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-13, accession 0001558370-25-007489.Report this figure57.6Cash and equivalents, Q2 FY2025, at 2025-06-30$57.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-12, accession 0001558370-25-011146.Report this figure52.8Cash and equivalents, Q3 FY2025, at 2025-09-30$52.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-10, accession 0001104659-25-109180.Report this figure46.3Cash and equivalents, FY2025, at 2025-12-31$46.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure33.3Cash and equivalents, Q1 FY2026, at 2026-03-31$33.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-12, accession 0001104659-26-058987.Report this figure24.2Cash and equivalents, Q2 FY2026, at 2026-06-30$24.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure
Current assets$m136Current assets, Q3 FY2023, at 2023-09-30$135.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-13, accession 0001558370-23-018686.Report this figure118Current assets, FY2023, at 2023-12-31$118.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-04, accession 0001558370-25-002101.Report this figure108Current assets, Q1 FY2024, at 2024-03-31$108.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-14, accession 0001558370-24-008058.Report this figure95.0Current assets, Q2 FY2024, at 2024-06-30$95.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0001558370-24-011463.Report this figure87.2Current assets, Q3 FY2024, at 2024-09-30$87.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-13, accession 0001558370-24-015431.Report this figure78.8Current assets, FY2024, at 2024-12-31$78.8m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-03, accession 0001104659-26-022549.Report this figure66.7Current assets, Q1 FY2025, at 2025-03-31$66.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-13, accession 0001558370-25-007489.Report this figure60.3Current assets, Q2 FY2025, at 2025-06-30$60.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-12, accession 0001558370-25-011146.Report this figure55.7Current assets, Q3 FY2025, at 2025-09-30$55.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-10, accession 0001104659-25-109180.Report this figure47.8Current assets, FY2025, at 2025-12-31$47.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure34.7Current assets, Q1 FY2026, at 2026-03-31$34.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-12, accession 0001104659-26-058987.Report this figure25.2Current assets, Q2 FY2026, at 2026-06-30$25.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure
Total assets$m169Total assets, Q3 FY2023, at 2023-09-30$169.3m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-13, accession 0001558370-23-018686.Report this figure151Total assets, FY2023, at 2023-12-31$150.5m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-04, accession 0001558370-25-002101.Report this figure141Total assets, Q1 FY2024, at 2024-03-31$140.5m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-14, accession 0001558370-24-008058.Report this figure125Total assets, Q2 FY2024, at 2024-06-30$125.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0001558370-24-011463.Report this figure112Total assets, Q3 FY2024, at 2024-09-30$111.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-13, accession 0001558370-24-015431.Report this figure102Total assets, FY2024, at 2024-12-31$102.4m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-03, accession 0001104659-26-022549.Report this figure86.0Total assets, Q1 FY2025, at 2025-03-31$86.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-13, accession 0001558370-25-007489.Report this figure79.2Total assets, Q2 FY2025, at 2025-06-30$79.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-12, accession 0001558370-25-011146.Report this figure74.2Total assets, Q3 FY2025, at 2025-09-30$74.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-10, accession 0001104659-25-109180.Report this figure62.3Total assets, FY2025, at 2025-12-31$62.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure36.5Total assets, Q1 FY2026, at 2026-03-31$36.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-12, accession 0001104659-26-058987.Report this figure25.2Total assets, Q2 FY2026, at 2026-06-30$25.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure
Current liabilities$m19.8Current liabilities, Q3 FY2023, at 2023-09-30$19.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-13, accession 0001558370-23-018686.Report this figure16.3Current liabilities, FY2023, at 2023-12-31$16.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-04, accession 0001558370-25-002101.Report this figure12.8Current liabilities, Q1 FY2024, at 2024-03-31$12.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-14, accession 0001558370-24-008058.Report this figure12.4Current liabilities, Q2 FY2024, at 2024-06-30$12.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0001558370-24-011463.Report this figure17.0Current liabilities, Q3 FY2024, at 2024-09-30$17.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-13, accession 0001558370-24-015431.Report this figure19.4Current liabilities, FY2024, at 2024-12-31$19.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-03, accession 0001104659-26-022549.Report this figure17.8Current liabilities, Q1 FY2025, at 2025-03-31$17.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-13, accession 0001558370-25-007489.Report this figure19.8Current liabilities, Q2 FY2025, at 2025-06-30$19.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-12, accession 0001558370-25-011146.Report this figure22.2Current liabilities, Q3 FY2025, at 2025-09-30$22.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-10, accession 0001104659-25-109180.Report this figure23.1Current liabilities, FY2025, at 2025-12-31$23.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure20.1Current liabilities, Q1 FY2026, at 2026-03-31$20.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-12, accession 0001104659-26-058987.Report this figure20.7Current liabilities, Q2 FY2026, at 2026-06-30$20.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure
Total liabilities$m43.0Total liabilities, Q3 FY2023, at 2023-09-30$43.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-13, accession 0001558370-23-018686.Report this figure39.3Total liabilities, FY2023, at 2023-12-31$39.3m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-04, accession 0001558370-25-002101.Report this figure35.6Total liabilities, Q1 FY2024, at 2024-03-31$35.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-14, accession 0001558370-24-008058.Report this figure34.8Total liabilities, Q2 FY2024, at 2024-06-30$34.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-08, accession 0001558370-24-011463.Report this figure39.0Total liabilities, Q3 FY2024, at 2024-09-30$39.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-13, accession 0001558370-24-015431.Report this figure41.2Total liabilities, FY2024, at 2024-12-31$41.2m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-03, accession 0001104659-26-022549.Report this figure39.3Total liabilities, Q1 FY2025, at 2025-03-31$39.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-13, accession 0001558370-25-007489.Report this figure40.9Total liabilities, Q2 FY2025, at 2025-06-30$40.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-12, accession 0001558370-25-011146.Report this figure43.0Total liabilities, Q3 FY2025, at 2025-09-30$43.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-10, accession 0001104659-25-109180.Report this figure43.5Total liabilities, FY2025, at 2025-12-31$43.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure24.7Total liabilities, Q1 FY2026, at 2026-03-31$24.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-12, accession 0001104659-26-058987.Report this figure20.7Total liabilities, Q2 FY2026, at 2026-06-30$20.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure
Shareholders' equity$m126Shareholders' equity, Q3 FY2023, at 2023-09-30$126.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-13, accession 0001558370-24-015431.Report this figure111Shareholders' equity, FY2023, at 2023-12-31$111.3m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-03, accession 0001104659-26-022549.Report this figure105Shareholders' equity, Q1 FY2024, at 2024-03-31$104.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-12, accession 0001558370-25-011146.Report this figure90.6Shareholders' equity, Q2 FY2024, at 2024-06-30$90.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001104659-25-109180.Report this figure72.7Shareholders' equity, Q3 FY2024, at 2024-09-30$72.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001104659-25-109180.Report this figure61.3Shareholders' equity, FY2024, at 2024-12-31$61.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure46.7Shareholders' equity, Q1 FY2025, at 2025-03-31$46.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure38.3Shareholders' equity, Q2 FY2025, at 2025-06-30$38.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure31.1Shareholders' equity, Q3 FY2025, at 2025-09-30$31.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001104659-25-109180.Report this figure18.8Shareholders' equity, FY2025, at 2025-12-31$18.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure11.8Shareholders' equity, Q1 FY2026, at 2026-03-31$11.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure4.5Shareholders' equity, Q2 FY2026, at 2026-06-30$4.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure

Cash flow

Operating cash flow−$9.2m, Q2 FY2026
Passage BIO, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(19.2)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$19.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-13, accession 0001558370-24-015431. Derived: 9-month figure less the 6-month figure.Report this figure(19.5)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$19.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-04, accession 0001558370-25-002101. Derived: 12-month figure less the 9-month figure.Report this figure(18.9)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$18.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-13, accession 0001558370-25-007489.Report this figure(13.1)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$13.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-12, accession 0001558370-25-011146. Derived: 6-month figure less the 3-month figure.Report this figure(7.4)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$7.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001104659-25-109180. Derived: 9-month figure less the 6-month figure.Report this figure(8.4)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$8.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-03, accession 0001104659-26-022549. Derived: 12-month figure less the 9-month figure.Report this figure(13.8)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$13.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001104659-26-058987.Report this figure(6.3)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$6.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001104659-26-093021. Derived: 6-month figure less the 3-month figure.Report this figure(4.9)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$4.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001104659-25-109180. Derived: 9-month figure less the 6-month figure.Report this figure(6.5)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$6.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-03, accession 0001104659-26-022549. Derived: 12-month figure less the 9-month figure.Report this figure(13.0)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$13.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001104659-26-058987.Report this figure(9.2)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$9.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001104659-26-093021. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)3.21m, Q2 FY2026
Passage BIO, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares54.5Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3054,473,945 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-13, accession 0001558370-23-018686.Report this figure54.6Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3154,618,799 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-14, accession 0001558370-24-008058.Report this figure54.7Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3054,683,817 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0001558370-24-011463.Report this figure54.8Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3054,789,410 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-13, accession 0001558370-24-015431.Report this figure56.3Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3156,295,540 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-13, accession 0001558370-25-007489.Report this figure3.1Diluted shares (weighted), Q2 FY2024, three months to 2024-06-303,142,537 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-12, accession 0001558370-25-011146.Report this figure3.1Diluted shares (weighted), Q3 FY2024, three months to 2024-09-303,146,582 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-10, accession 0001104659-25-109180.Report this figure3.2Diluted shares (weighted), Q1 FY2025, three months to 2025-03-313,163,914 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-12, accession 0001104659-26-058987.Report this figure3.2Diluted shares (weighted), Q2 FY2025, three months to 2025-06-303,168,933 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure3.2Diluted shares (weighted), Q3 FY2025, three months to 2025-09-303,178,710 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-10, accession 0001104659-25-109180.Report this figure3.2Diluted shares (weighted), Q1 FY2026, three months to 2026-03-313,205,866 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-12, accession 0001104659-26-058987.Report this figure3.2Diluted shares (weighted), Q2 FY2026, three months to 2026-06-303,208,744 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure

Shares outstanding: 3.22mShares outstanding, period not labelled, at 2026-08-053,217,810 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-10, accession 0001104659-26-093021.Report this figure at Aug 5, 2026, from the cover of the 10-Q filed Aug 10, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. Listed shows no prices and gives no investment advice.